Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HP Inc (HPQ) vs Pfizer Inc (PFE) Price & Performance

Pfizer IncTrade

Price performance (Past 24H)

Key statistics

HP Inc vs Pfizer Inc — how do they compare? HP Inc trades at $28.79 (market cap $26.59B), while Pfizer Inc trades at $26.28 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 5.7× HP Inc's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.

HPQPFE
Market Cap
$26.59B$151.73B
Sector
TechnologyHealth
52-Week High
$30.05$28.56
52-Week Low
$18.20$23.60
Enterprise Value
$33.75B$203.22B
Dividend Yield
4.13%6.46%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HP Inc

HPQ trades at $28.72, down 3.62% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $55.3B in 2025, though net margins compressed to 4.45%. The stock offers a dividend yield near 4% and trades at attractive valuations with a P/E of 10.77 and P/S of 0.48. Recent news highlights AI-driven cost savings and a potential 2027 upgrade cycle, while institutional activity shows mixed positioning adjustments.

Outlook: HPQ presents value with low multiples and dividend income, but faces PC market volatility and margin pressure. Risks include competitive threats and debt levels, while catalysts include AI product adoption. Analyst consensus is mixed with a hold rating, but technical strength and earnings consistency support cautious optimism for patient investors.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About HP Inc

HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.

Read more on HPQ

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE